Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,070.94 -11.25 (-1.04%)
Streaming Delayed Price Updated: 2:57 PM EDT, Aug 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 321,802
Open 1,082.00
Bid (Size) 1,069.77 (3)
Ask (Size) 1,072.11 (2)
Prev. Close 1,082.19
Today's Range 1,050.01 - 1,090.42
52wk Range 765.28 - 1,115.00
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Regeneron Pharmaceuticals Due for a Stock Split?
Would a stock split help lead Regeneron Pharmaceuticals shares higher? 
Via The Motley Fool
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+18.34%
+18.34%
1 Month
+3.55%
+3.55%
3 Month
+11.71%
+11.71%
6 Month
+14.38%
+14.38%
1 Year
+38.23%
+38.23%

More News

Read More
Analyst Ratings For Regeneron Pharmaceuticals
Via Benzinga
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Via Benzinga
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Via Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
Via Investor's Business Daily
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
Via Benzinga
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Via Benzinga
Regeneron Reports Second Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Via Benzinga
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Via Benzinga
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Via Benzinga
3 Standout Stocks to Buy for the Next Bull Market
Via InvestorPlace
Stocks to Buy: 7 Founder-Led Companies Set to Outperform
Via InvestorPlace
CPI Data Sparks Rally in Biotech Stocks
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.